Aak1 to increase infiltration of adoptively transferred cells into solid tumors

Aak1 增加过继转移细胞向实体瘤的浸润

基本信息

  • 批准号:
    10558244
  • 负责人:
  • 金额:
    $ 45.76万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-02-16 至 2028-01-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY/ABSTRACT Insufficient T cell infiltration is a major challenge in adoptive transfer therapies like CAR-T. Therefore, one strategy to improve therapy is to enhance T cell trafficking into tumors. However, current therapies targeting T cell activities largely consist of immune checkpoint modulators, and very little innovation has occurred in therapeutic design targeting T cell intrinsic regulators of intratumoral accumulation. This is due, in part, to an incomplete understanding of the regulatory pathways involved in T cell trafficking. We recently identified Adapter protein 2 associated kinase 1 (Aak1) as an important regulator of T cell chemotaxis into tumors in an in vivo forward genetic screen. The primary objective of this project is to measure the translational potential of AAK1 as a therapeutic target in cancer to augment adoptive transfer therapies, with the additional goal of better understanding molecular functions of Aak1 as a regulator of chemokine receptor Cxcr3 internalization. These goals will be accomplished in three aims. Aim 1 will quantify the impact of genetic modification of Aak1 on tumor infiltration of adoptively transferred T cells in a preclinical solid tumor model. Aim 2 will determine whether Aak1 kinase activity is required for chemokine-induced internalization of Cxcr3 in primary T cells. Aim 3 will measure the degree to which Aak1 modification impacts therapeutic efficacy in adoptive transfer therapies. This proposal has several innovative aspects, including characterization of a novel, T cell specific Aak1 knockout mouse, functional and mechanistic testing of a novel Aak1 mutant construct, and evaluation of Aak1 as a novel therapeutic target to limit T cell chemotaxis into inflamed tissue. Successful completion of this project will benefit development of novel treatment strategies for solid tumors, and findings can broadly be applied to any T cell adoptive transfer approach and is not limited to individual CAR or TCR engineered platforms.
项目总结/摘要 T细胞浸润不足是CAR-T等过继转移疗法的主要挑战。因此,一 改善治疗的策略是增强T细胞向肿瘤中的运输。然而,目前针对T 细胞活动主要由免疫检查点调节剂组成,而且几乎没有创新 靶向肿瘤内积累的T细胞内在调节因子的治疗设计。这在一定程度上是由于 对参与T细胞运输的调节途径的不完全理解。我们最近发现适配器 蛋白2相关激酶1(Aak 1)作为体内T细胞趋化性进入肿瘤的重要调节因子, 遗传筛查该项目的主要目的是测量AAK 1的翻译潜力, 癌症的治疗靶点,以增强过继转移治疗,其额外目标是更好地 了解Aak 1作为趋化因子受体Cxcr 3内化调节剂的分子功能。这些 目标将在三个方面实现。目的1:量化Aak 1基因修饰对肿瘤的影响 在临床前实体瘤模型中过继转移的T细胞的浸润。目标2将决定Aak 1是否 激酶活性是趋化因子诱导的Cxcr 3在原代T细胞中内化所必需的。目标3将衡量 Aak 1修饰在何种程度上影响过继转移治疗的疗效。这项建议 具有几个创新方面,包括表征一种新的T细胞特异性Aak 1敲除小鼠, 新的Aak 1突变体构建体的功能和机制测试,以及Aak 1作为新的 治疗靶点,以限制T细胞趋化性进入发炎组织。该项目的成功完成将使 开发新的实体瘤治疗策略,研究结果可广泛应用于任何T细胞 本发明的CAR或TCR工程化平台可以是过继转移方法,并且不限于单独的CAR或TCR工程化平台。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Laura Marie Rogers其他文献

Laura Marie Rogers的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Laura Marie Rogers', 18)}}的其他基金

Understanding the impact of AAK1 on T cell chemokine receptor expression and chemotaxis
了解 AAK1 对 T 细胞趋化因子受体表达和趋化性的影响
  • 批准号:
    10300774
  • 财政年份:
    2021
  • 资助金额:
    $ 45.76万
  • 项目类别:
Rationally improving T cell-mediated immunotherapy using Sleeping Beauty mutagenesis
利用睡美人诱变合理改进 T 细胞介导的免疫治疗
  • 批准号:
    10238780
  • 财政年份:
    2019
  • 资助金额:
    $ 45.76万
  • 项目类别:
Rationally improving T cell-mediated immunotherapy using Sleeping Beauty mutagenesis
利用睡美人诱变合理改进 T 细胞介导的免疫治疗
  • 批准号:
    9503289
  • 财政年份:
    2019
  • 资助金额:
    $ 45.76万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了